A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder

P. Czobor, Phil Skolnick, Bernard Beer, Arnold Lippa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Preclinical studies demonstrated that ocinaplon, a positive allosteric modulator of GABAA receptors, possesses anxiolytic-like actions at doses devoid of the side effects typically associated with benzodiazepines. The aim of this study was to evaluate the effects of ocinaplon in a multicenter, double-blind proof-of-concept trial of male and female outpatients who met DSM-IV criteria for GAD with no coexisting depression, and had a baseline score of ≥20 on the Hamilton Scale for Anxiety (HAM-A). Patients with

Original languageEnglish
Pages (from-to)63-75
Number of pages13
JournalCNS Neuroscience and Therapeutics
Volume16
Issue number2
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Anxiety Disorders
Double-Blind Method
Placebos
Safety
Anti-Anxiety Agents
GABA-A Receptors
Benzodiazepines
Diagnostic and Statistical Manual of Mental Disorders
Outpatients
Anxiety
Depression
ocinaplon

Keywords

  • Anxiety
  • GABA(A) receptor modulator
  • GAD
  • Ocinaplon
  • Selective anxiolysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Physiology (medical)
  • Psychiatry and Mental health
  • Pharmacology

Cite this

A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder. / Czobor, P.; Skolnick, Phil; Beer, Bernard; Lippa, Arnold.

In: CNS Neuroscience and Therapeutics, Vol. 16, No. 2, 04.2010, p. 63-75.

Research output: Contribution to journalArticle

@article{b140eb18ffaf44c18ccef4d1879fab46,
title = "A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder",
abstract = "Preclinical studies demonstrated that ocinaplon, a positive allosteric modulator of GABAA receptors, possesses anxiolytic-like actions at doses devoid of the side effects typically associated with benzodiazepines. The aim of this study was to evaluate the effects of ocinaplon in a multicenter, double-blind proof-of-concept trial of male and female outpatients who met DSM-IV criteria for GAD with no coexisting depression, and had a baseline score of ≥20 on the Hamilton Scale for Anxiety (HAM-A). Patients with",
keywords = "Anxiety, GABA(A) receptor modulator, GAD, Ocinaplon, Selective anxiolysis",
author = "P. Czobor and Phil Skolnick and Bernard Beer and Arnold Lippa",
year = "2010",
month = "4",
doi = "10.1111/j.1755-5949.2009.00109.x",
language = "English",
volume = "16",
pages = "63--75",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder

AU - Czobor, P.

AU - Skolnick, Phil

AU - Beer, Bernard

AU - Lippa, Arnold

PY - 2010/4

Y1 - 2010/4

N2 - Preclinical studies demonstrated that ocinaplon, a positive allosteric modulator of GABAA receptors, possesses anxiolytic-like actions at doses devoid of the side effects typically associated with benzodiazepines. The aim of this study was to evaluate the effects of ocinaplon in a multicenter, double-blind proof-of-concept trial of male and female outpatients who met DSM-IV criteria for GAD with no coexisting depression, and had a baseline score of ≥20 on the Hamilton Scale for Anxiety (HAM-A). Patients with

AB - Preclinical studies demonstrated that ocinaplon, a positive allosteric modulator of GABAA receptors, possesses anxiolytic-like actions at doses devoid of the side effects typically associated with benzodiazepines. The aim of this study was to evaluate the effects of ocinaplon in a multicenter, double-blind proof-of-concept trial of male and female outpatients who met DSM-IV criteria for GAD with no coexisting depression, and had a baseline score of ≥20 on the Hamilton Scale for Anxiety (HAM-A). Patients with

KW - Anxiety

KW - GABA(A) receptor modulator

KW - GAD

KW - Ocinaplon

KW - Selective anxiolysis

UR - http://www.scopus.com/inward/record.url?scp=77749286348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749286348&partnerID=8YFLogxK

U2 - 10.1111/j.1755-5949.2009.00109.x

DO - 10.1111/j.1755-5949.2009.00109.x

M3 - Article

VL - 16

SP - 63

EP - 75

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 2

ER -